Shop Apotheke Europe N.V. provided earnings guidance for the year 2022. For the full year 2022, the management board of the company confirms the guidance for the ongoing business given at the start of the year, of sales growth of everything-but-Rx of 15% to 25%.
Market Closed -
Other stock markets
|
After market 02:49:09 pm | |||
120.5 EUR | +0.42% | 120.2 | -0.25% |
Apr. 26 | REDCARE PHARMACY : Deutsche Bank reiterates its Buy rating | ZD |
Apr. 26 | REDCARE PHARMACY : Hauck & Aufhauser keeps its Buy rating | ZD |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.43% | 2.63B | |
-30.07% | 15.43B | |
-20.84% | 12.31B | |
-24.53% | 6.59B | |
+12.34% | 6.3B | |
-8.87% | 5.88B | |
-1.17% | 4.74B | |
+60.03% | 4.7B | |
-4.98% | 4.03B | |
-8.59% | 3.58B |
- Stock Market
- Equities
- RDC Stock
- News Redcare Pharmacy NV
- Shop Apotheke Europe N.V. Provides Earnings Guidance for the Year 2022